Open Access
ND 2007
Article Number 361
Number of page(s) 4
Section Medical and environmental applications
Published online 17 June 2008
International Conference on Nuclear Data for Science and Technology 2007
DOI: 10.1051/ndata:07668

IAEA coordinated research programme: nuclear data for the production of therapeutic radionuclides

R. Capote1, E. Beták2, B.V. Carlson3, H.D. Choi4, A. Ignatyuk5, E. Menapace6, F.M. Nortier7, S.M. Qaim8, B. Scholten8, Y.N. Shubin5, J.C. Sublet9 and F.T. Tarkanyi10

1  Nuclear Data Section, International Atomic Energy Agency, 1400 Vienna, Austria
2  Institute of Physics, Slovak Academy of Science, 84511 Bratislava, Slovakia
3  Instituto Tecnológico de Aeronáutica, 12228-900 São Jose dos Campos SP, Brazil
4  Department of Nuclear Engineering, Seoul National University, Seoul 151-744, Korea
5  Institute of Physics and Power Engineering, 249020 Obninsk, Russian Federation
6  ENEA - Applied Physics Division, C.R. ``E. Clementel'', 40138 Bologna, Italy
7  Los Alamos National Laboratory, Inorganic and Isotopes Chemistry Group, NM 7545, USA
8  Institut für Nuklearchemie, Forschungszentrum Jülich GmbH, 52425 Jülich, Germany
9  CEA Cadarache, 13108 Saint-Paul-lez-Durance Cedex, France
10  Cyclotron Department, Institute of Nuclear Research of the Hungarian Academy of Sciences, 4001 Debrecen, Hungary

Published online: 21 May 2008

The need for radioisotopes in cancer therapy is very well established. With a view to providing standardised data for the production of relevant radioisotopes an IAEA Coordinated Research Project on ``Nuclear Data for the Production of Therapeutic Radionuclides'' was started in 2003, and is now close to completion. Experimental data compilations, theoretical calculations and evaluations were carried out for each of the reactions. The recommendations for both established and emerging radionuclides are discussed. Examples of the analyses carried out to produce the recommended data for some radionuclides are also presented. The improved quality of the nuclear data will make reactor and accelerator production of therapeutic radionuclides much more efficient and effective, and should also enhance their quality through improved purity.

© CEA 2008